contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


spectracure-strengthens-presence-among-urologists

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

SpectraCure is a medical technology company The company specializes in the research and development of medical technology systems used to treat prostate cancer. The cancer treatments are based on proprietary systems that emit laser light sources and photoreactive drugs, a treatment methodology used for internally solid tumors of various types. The company operates in the Nordic market. The head office is located in Lund. 

SpectraCure

SpectraCure AB has for four days participated with a stand at Urologiveckan, the annual conference gathering Sweden's top urologists, urology nurses, and researchers. This presence enhances ...

<div class="mfn-preamble"><p><strong>SpectraCure AB has for four days participated with a stand at Urologiveckan, the annual conference gathering Sweden's top urologists, urology nurses, and researchers. This presence enhances SpectraCure's relationship with leading urologists.</strong></p></div><div class="mfn-body"><p>At this year's Urologivecka in Sundsvall, SpectraCure demonstrated the system and highlighted the company's ongoing clinical study. The conference serves as a strategic platform to establish SpectraCure's presence among urologists and raises at the same time awareness of the ongoing clinical study.</p><blockquote>“These past four days have been filled with interesting meetings and discussions with urologists and nurses who have shown interest in our method. There is a clear consensus and a desire to explore and develop new focal treatment options for patients affected by recurrent prostate cancer," says Kristina Holst, Head of Clinical Affairs, SpectraCure.</blockquote><blockquote>"We can build strong relationships with leading urologists through active participation and visibility in these contexts. This enables us to establish SpectraCure as a trustworthy and reliable player in the industry and also to increase awareness of the ongoing clinical study," says Masoud Khayyami, acting CEO, SpectraCure.</blockquote></div><div class="mfn-footer mfn-contacts mfn-6558016d3d86"><p><strong class="mfn-heading-1">For further information:</strong><br>Masoud Khayyami, Acting CEO<br>E-mail:&nbsp;<a rel="noopener" href="http://jf@spectracure.com/">mk@spectracure.com</a><a rel="noopener" href="http://jf@spectracure.com/"><br></a>Website:&nbsp;<a rel="noopener" href="https://spectracure.com/">www.spectracure.com</a></p></div><div class="mfn-footer mfn-about mfn-a7fe56d25f6e"><p><strong>SpectraCure</strong> is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer, with the hope of being able to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system, Q-PRO®, consisting of a hardware device, a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, safe for every patient. The goal is that in addition to being tumor free, the patient will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system.&nbsp;</p><p>The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&amp;W Fondkommission as Certified Adviser, and trades under the short name SPEC.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/c7816877-701c-4e17-84b6-4fab9e6471d7/spectracure-strengthens-presence-among-urologists.pdf" class="mfn-generated mfn-primary">SpectraCure strengthens presence among urologists</a></p></div>

Stay up to date with our newsletter